## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.22 indicates fundamental undervaluation. Quality metrics strong (ROE 136%, ROA 12%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-3.9% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($461.95)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 8, Bearish: 0)

**1. Artificial Intelligence at HCA Healthcare â€“ Two Use Cases**
- Source: Emerj Artificial Intelligence Research | 20251208T111621 | Bullish | Relevance: 99%
-  HCA Healthcare is leveraging AI in two key areas. First, they partnered with Google Cloud and Commure to implement generative AI for clinical documentation, aiming to improve workflow efficiency and free up clinicians' time. Second, they collaborated with GE HealthCare to develop CareIntellect for Perinatal, a cloud-based platform utilizing AI and predictive analytics to centralize maternal and fetal data, detect risks earlier, and strengthen perinatal outcomes.

**2. Invesco Ltd. Sells 113,115 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251206T112555 | Somewhat-Bullish | Relevance: 99%
- Invesco Ltd. reduced its stake in HCA Healthcare, Inc. by 9.4% in the second quarter, selling 113,115 shares and now owning 1,089,100 shares valued at $417,234,000. Other institutional investors also adjusted their positions in HCA, while analysts have given the stock a "Moderate Buy" consensus rating with an average target price of $474.53. Insider selling occurred recently, with EVP Michael R. Mcalevey and EVP Michael S. Cuffe selling shares.

**3. California Public Employees Retirement System Has $124.64 Million Stock Position in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251208T094854 | Bullish | Relevance: 99%
-  The California Public Employees' Retirement System (CalPERS) recently reduced its HCA Healthcare (NYSE:HCA) holdings by 5.4%, but still maintains a significant position worth approximately $124.64 million. This move comes as other institutional investors, such as Norges Bank and Price T Rowe Associates Inc. MD, have either initiated or significantly boosted their stakes in the company. HCA Healthcare reported strong Q3 earnings, surpassing analyst estimates, and announced a quarterly dividend, indicating healthy financial performance and a commitment to shareholder returns.

**4. CW Advisors LLC Has $3.31 Million Position in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251207T092016 | Bullish | Relevance: 98%
-  CW Advisors LLC significantly increased its stake in HCA Healthcare by 576.9% in Q2, bringing its total holdings to 8,644 shares valued at approximately $3.31 million. HCA Healthcare exceeded Q3 expectations with EPS of $6.96 and $19.16 billion in revenue, setting positive FY2025 guidance. Analysts maintain a "Moderate Buy" rating with a consensus price target of $474.53 for the company.

**5. Amundi Boosts Holdings in HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251208T130804 | Bullish | Relevance: 98%
-  Amundi significantly increased its stake in HCA Healthcare by 36.2% in Q2, bringing its total holdings to 394,665 shares valued at $149.2 million. This comes as HCA Healthcare reported strong Q3 earnings, surpassing expectations with an EPS of $6.96 and revenue of $19.16 billion, leading to several analyst price target increases and a "Moderate Buy" consensus rating. Despite an insider sale by EVP Michael R. McAlevey, institutional investors collectively own a substantial 62.7% of the company, and the company announced a quarterly dividend of $0.72 per share.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Wells Fargo | $431 | $412 | +5% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Wells Fargo | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.9% 5d) with bearish MACD, trend may be turning.
2. Heavy insider selling: $15M sold (4 transactions in 90 days).
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.22 suggests fair value with growth premium. Forward P/E 16.3x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $113.5B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 2.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.22 |
| Forward P/E | 16.3 |
| Current P/E | 17.6 |
| YoY Growth | 7.7% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 1.6% to -2.4% (-3.9% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.3pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.25x) but short-term weakness (below SMA20). MACD histogram bearish (-3.11), momentum weakening. RSI neutral at 53.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.35% (CS: 38) | Weak |
| RSI_14 | 53.4 | Neutral |
| MACD Histogram | -3.11 | Bearish |
| vs SMA20 | 0.997x | Below |
| vs SMA50 | 1.056x | Above |
| vs SMA200 | 1.248x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $485.15
- **Stop Loss:** $461.95 (4.8% risk)
- **Target:** $531.55 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 21
- **Position Value:** $10,188.15
- **Portfolio %:** 10.19%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*